Led by Professor Takaaki Abe at Tohoku University Graduate School of Medicine, the team discovered that a medicine usually ...

Progenics could receive $20 million in milestones. Ono Pharmaceutical is paying $15 million for rights to develop Progenics Pharmaceuticals’ opioid-induced constipation drug, Relistor®, in Japan.

Sucampo Pharma, Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (SPI) has received approval from the Ministry of Health, Labor and Welfare in Japan for Amitiza (lubiprostone), a ...

— Albireo subsidiary eligible to receive up to $60 million under agreement — — Decision on Japanese New Drug Application for elobixibat expected in first half of 2018 — BOSTON, Jan. 03, 2018 (GLOBE ...

Sweden's Albireo has reached a licensing deal with a Japanese drugmaker, giving Ajinomoto Pharmaceuticals the rights to develop and market a constipation drug in Japan, South Korea, Thailand, ...

The global market for Constipation Treatment was valued at US$19.5 Billion in 2024 and is projected to reach US$27.5 Billion by 2030, growing at a CAGR of 5.9% from 2024 to 2030.

(Reuters) - U.S. drugmaker Sucampo Pharmaceuticals is seeking talks with marketing partner Takeda Pharmaceutical Co Ltd to mend their relationship, after losing a two-year legal battle to sever ties ...

Photo Taken In Bangkok, Thailand Constipation has long been thought of as a benign condition and one better suited for self-management, but if left untreated, it could lead to a host of other medical ...